Dr. Sheila Gujrathi is a physician-executive with a deep track record in translational science and drug development. She currently sits on the board for Ventyx Biosciences, IMMPACT Bio, ADARx Pharmaceuticals, and Janux Therapeutics and is prior Venture Advisor at OrbiMed and prior chair of Turning Point Therapeutics. She is co-founder and former CEO of Gossamer Bio, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Prior to Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos, which was acquired by Celgene in 2015. Prior to Receptos, Dr. Gujrathi was Vice President of the Global Clinical Development Group in Immunology at Bristol-Myers Squibb, where she led clinical development and supported numerous global regulatory filings and approvals for Orencia® and Nulojix®. Prior to Bristol-Myers Squibb, Dr. Gujrathi held roles in the immunology, tissue growth and repair clinical development groups at Genentech.